GSK plc’s BioNTech BNTX Stock Holding History

GSK plc’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$82.8M	Hold	889,824	–	–	13.75%	4
2026 Q1	$79.1M	Hold	889,824	–	–	13.2%	3
2025 Q4	$84.7M	Buy	+889,824	New	+$89.6M	10.6%	3

Other funds holding BNTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Flossbach Von Storch Cologne, Germany $22.1B AUM 6.81% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

GSK plc's BNTX Position: Q2 2026 in Review

GSK plc held its BioNTech (BNTX) position steady in Q2 2026 at 889,824 shares worth $82.8M. The position accounts for 13.75% of the portfolio, ranked #4.

GSK plc first reported a position in BNTX in Q4 2025 and has held it in 3 quarters since. The position peaked at $84.7M in Q4 2025. 282 funds tracked by Wall St. Rank hold BNTX as of Q2 2026.

GSK plc held 889,824 shares of BioNTech worth $82.8M as of Q2 2026.
GSK plc left its BioNTech share count unchanged in Q2 2026.
BioNTech made up 13.75% of GSK plc's portfolio in Q2 2026, its #4 holding.
GSK plc first reported a position in BioNTech in Q4 2025 and has held it in 3 quarters since.
GSK plc's BioNTech position peaked at $84.7M in Q4 2025.
282 funds tracked by Wall St. Rank held BioNTech as of Q2 2026.

Based on GSK plc's 13F filing for Q2 2026, filed 13 Aug 2026.